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Abstract: In 2 double-blind phase 3 trials, 1733 antiretroviral-
naive adults were randomized to tenofovir alafenamide (TAF) or
tenofovir disoproxil fumarate (TDF), each coformulated with
elvitegravir/cobicistat/emtricitabine (E/C/F). At 144 weeks,
TAF was superior to TDF in virologic efficacy, with 84.2% vs
80.0% having HIV-1 RNA ,50 copies/mL (difference 4.2%;
95% confidence interval: 0.6% to 7.8%). TAF had less
impact than TDF on bone mineral density and renal biomarkers.
No participants on TAF had renal-related discontinuations vs
12 on TDF (P , 0.001), with no cases of proximal tubulopathy
for TAF vs 4 for TDF. There were greater increases in
lipids with TAF vs TDF, with no difference in the total
cholesterol to high-density lipoprotein ratio. For initial HIV
therapy, E/C/F/TAF is superior to E/C/F/TDF in efficacy and
bone and renal safety.
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INTRODUCTION
Use of tenofovir disoproxil fumarate (TDF)-based
regimens is highly effective but may be associated with
renal and bone toxicity, attributed to high circulating plasma
levels of tenofovir (TFV).1–5 By contrast, use of tenofovir
alafenamide (TAF)-based regimens has less impact on
measures of renal and bone safety, attributed to significantly
lower plasma TFV levels while increasing delivery of
intracellular TFV-diphosphate, the active moiety of both
compounds.6
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In treatment-naive individuals and those switching from
TDF-containing regimens, the single-tablet coformulation of
elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) demon-
strated high efficacy and significantly reduced effects on
estimated glomerular filtration rate (eGFR), proteinuria, albu-
minuria, and bone mineral density (BMD) compared with TDF-
containing regimens.6–9 Treatment-naive participants in 2 large
randomized, international, double-blind, placebo-controlled trials
(GS-US-292-0104 and GS-US-292-0111, ClinicalTrials.gov
numbers NCT01780506 and NCT01797445) who received
TAF had significantly less bone demineralization in the lumbar
spine and total hip and significantly lower rates of total
proteinuria, albuminuria, and proximal tubular proteinuria at
weeks 48 and 96 compared with those on TDF.6,7
Given these efficacy and safety data, E/C/F/TAF has
become a recommended initial regimen in the HIV treatment
guidelines for the United States (U.S.) and Europe.10–16
However, the durability of virologic response and the
persistence of the favorable effects of TAF compared with
TDF on renal and bone safety parameters are of long-term
interest because HIV-infected patients who initiate TAF-
containing regimens could anticipate receiving lifelong
therapy. We present efficacy and safety data from these trials
through 144 weeks of blinded treatment.
METHODS
Study Design and Participants
Details on design, inclusion criteria, and methodology of
the trials have been previously reported.6 Briefly, antiretroviral
treatment–naive adults were randomized 1:1 to once-daily TAF
10 mg vs TDF 300 mg, both coformulated with elvitegravir 150
mg, cobicistat 150 mg, and emtricitabine 200 mg (E/C/F). The
studies were approved by the U.S. Food and Drug Administra-
tion (FDA) and institutional review boards at all sites.
Statistical Analysis
Pooled analyses of week 144 data from both studies
were prespecified in the protocols and analysis plans.
Efficacy was assessed by examining the proportion in each
group with plasma HIV-1 RNA ,50 copies/mL at week 144
(U.S. FDA–defined snapshot algorithm).17 A 12% margin
and 2-sided 95% confidence interval (CI) (unadjusted alpha
level) were used to establish noninferiority; once estab-
lished, the same CI was prespecified for use to evaluate
superiority. An identical approach was applied using
a plasma HIV-1 RNA threshold of ,20 copies/mL. Adverse
events (AEs) were coded with the Medical Dictionary for
Regulatory Activities (version 19.0). The Fisher exact test
was used to compare differences for AEs and Wilcoxon
rank-sum test to compare differences for continuous labo-
ratory test results (SAS; version 9.2). A post hoc evaluation
of proximal renal tubulopathy was performed using the
following confirmed criteria: rise in serum creatinine $0.4
mg/dL, dipstick proteinuria $2 grade-level increase from
baseline in urine protein, normoglycemic glycosuria, and a 1
grade-level change in serum hypophosphatemia.
RESULTS
A total of 1733 adults received at least 1 dose of study
drug: 866 TAF and 867 TDF. Baseline characteristics were
similar between groups (Table S1 http://links.lww.com/QAI/
A986), with similar rates of retention through week 144 (TAF
85% vs TDF 82%).
At 144 weeks, 84.2% of participants receiving TAF and
80.0% receiving TDF had HIV-1 RNA ,50 copies/mL (U.S.
FDA–defined snapshot algorithm) using the full analysis set
(difference 4.2%; 95% CI: 0.6% to 7.8%) (Fig. 1). Treatment
discontinuation (primarily due to AEs or withdrawal of con-
sent, among other reasons not related to efficacy) contributed
to the lower percentage of virologic success with TDF.
Analyses comparing rates of virologic suppression between
treatments within prespecified subgroups favored TAF over
TDF at week 144 for those with baseline HIV-1 RNA
#100,000 copies/mL, those with baseline CD4 count $200
cells/mL, women, adults $50 years of age, nonblack partic-
ipants, and those with an adherence rate of $95% (Figure S1
http://links.lww.com/QAI/A986). At 144 weeks, 81.1% on
TAF and 75.8% on TDF had HIV-1 RNA,20 copies/mL (U.
S. FDA–defined snapshot algorithm) (difference 5.4%;
FIGURE 1. Virologic outcomes at weeks 48, 96, and 144. 
47.3%, TDF 71.8%; P , 0.001) (Fig. 2A). Median values for
each group remained within the normal range. Fewer
participants on TAF compared with TDF initiated calcium,
vitamin D, or other nutritional supplements during the study
(16.2% vs 20.7%, P = 0.018).
Median change from baseline in creatinine clearance
(CrCl; eGFR by Cockcroft Gault) was significantly lower
with TAF (21.6 mL/min) than TDF (–7.7 mL/min) at week
144 (P , 0.001) (Fig. 2B). At week 144, significantly fewer
participants on TAF (17.6%) had a clinically meaningful
decrease of $25% from baseline in CrCl compared with TDF
(33.4%) (P , 0.001). A quantitative marker of proteinuria
(urine protein to creatinine ratio) and specific markers of
proximal tubular proteinuria (retinol-binding protein/Cr and
b-2-microglobulin/Cr) increased from baseline with TDF,
whereas decreases or smaller increases were observed with
TAF (P , 0.001) (Figs. 2B, C). Fewer participants on TAF
developed clinically significant proteinuria (urine protein to
creatinine ratio .200 mg/g) (n = 22 vs 40, P = 0.016 for
difference in distribution of changes above and below
200 mg/g).
No study drug discontinuations due to renal events
occurred with TAF, whereas 12 participants discontinued
TDF because of renal-related AEs (P , 0.001) (Table S2
http://links.lww.com/QAI/A986): 4 before week 48, 2
between weeks 48 and 96, and 6 after week 96. No cases
of proximal tubulopathy occurred in the TAF group,
whereas 4 participants receiving TDF had investigator-
reported tubulopathy. Seven participants on TDF met
laboratory criteria for proximal renal tubulopathy (Tables S3
and S4 http://links.lww.com/QAI/A986), including 4 of the 12
discontinued participants.
There were greater median increases in total cholesterol
(TC), high-density lipoprotein (HDL), low-density lipopro-
tein, and triglycerides in the TAF group compared with the
TDF group (P , 0.001), whereas there were no differences in
the median TC to HDL ratio between groups (P . 0.72 for
weeks 48, 96, and 144) (Fig. 3). There were no differences
between TAF and TDF in cardiovascular or cerebrovascular
events: 24 participants (2.8%) vs 33 (3.8%) (P = 0.28),
serious cardiovascular or cerebrovascular events: 5 (0.6%) vs
6 (0.7%) (P = 1.00), or use of lipid-modifying agents: 48
(5.5%) vs 50 (5.8%) (P = 0.92).
DISCUSSION
After 144 weeks of treatment, a TAF-based single-
tablet regimen maintained a high rate of virologic suppression
in treatment-naive participants (84%) and met prespecified
criteria for both noninferiority and superiority to a TDF-based
similar combination, using a priori cutoffs of HIV-1 RNA
,50 and ,20 copies/mL. Concordant with this durable high
level of suppression was the rare emergence of antiretroviral
resistance (1.4%).
During this extended period of study, both study
regimens continued to be well tolerated. As we have pre-
viously reported, the majority of the most common AEs
occurred within the first 4 weeks of treatment initiation.18 Of
note, not only did fewer participants on TAF discontinue
95% CI: 1.5% to 9.2%). CD4 cell counts increased in both 
groups, with mean (SD) changes from baseline of 326 (215.3) 
cells/mL for TAF and 305 (204.5) cells/mL for TDF (P = 0.062)  
at week 144.
By 144 weeks, virologic failure with resistance 
occurred in 24 participants: 12 (1.4%) on TAF vs 12 
(1.4%) on TDF. Genotypic resistance data: nucleoside 
reverse-transcriptase inhibitor (NRTI) and Elvitegravir 
(EVG) resistance (n = 8), NRTI resistance only (n = 4) in 
the TAF group; NRTI and EVG resistance (n = 7), NRTI 
resistance only (n = 4), EVG resistance only (n = 1) in the 
TDF group. Two participants on TAF and 4 on TDF had 
newly detected genotypic resistance between weeks 96 and 
144. In those with genotypic resistance, there was no 
statistical difference in median baseline viral load between 
TAF and TDF (252,200 vs 115,500 HIV-1 RNA copies/mL; 
P = 0.270).
Both regimens continued to be well tolerated through 
week 144, with similar rates of drug-related AEs with TAF 
(44.1%) and TDF (48.9%). The most common drug-related 
AEs in both groups were nausea (TAF 10.5%, TDF 13.3%), 
diarrhea (TAF 7.3%, TDF 8.9%), and headache (TAF 6.1%, 
TDF 5.4%). AEs leading to study drug discontinuation 
occurred in 11 participants (1.3%) on TAF vs 29 (3.3%) on 
TDF (Table S2 http://links.lww.com/QAI/A986). AEs lead-
ing to drug discontinuation in the TAF group occurred 
predominantly within the first 48 weeks, whereas those in 
the TDF group continued at a similar frequency through 144 
weeks [cumulative events in TAF vs TDF at 48, 96, and 144 
weeks: n = 8 vs n = 13 (P = 0.380); 10 vs 20 (P = 0.096); and 
11 vs 29 (P = 0.006)]. Incidence of serious AEs was low and 
similar between groups (TAF 14.0%, TDF 14.3%). Serious 
AEs considered drug related by the investigator occurred in 5 
participants (0.6%) on TAF (abdominal pain, staphylococcal 
skin infection, rotator cuff syndrome, erythematous rash, and 
hypovolemic shock) and 6 participants (0.7%) on TDF 
(spontaneous abortion, immune reconstitution inflammatory 
syndrome, acute pancreatitis, cholelithiasis, acute coronary 
syndrome, and drug interaction). Incidence of grade 3 or 4 
laboratory abnormalities was similar between groups (TAF 
32.9% vs TDF 30.8%); the most common was elevated 
creatine kinase (TAF 11.5% vs TDF 10.1%).
Participants receiving TAF had significantly smaller 
declines in total hip and lumbar spine BMD than those 
receiving TDF through week 144 (% change from baseline at 
week 144: hip: TAF 20.75%, TDF 23.36%; spine: TAF 
20.92%, TDF 22.95%) (P , 0.001) (Fig. 2A). More 
participants on TAF recovered from osteopenia or osteopo-
rosis at either the hip (TAF n = 14 vs TDF n = 10) or spine 
(TAF n = 24 vs TDF n = 10) by week 144 (P , 0.001 for 
difference in distribution of clinical BMD status). Fractures 
were rare, reported for 6 participants (0.7%) on TAF and 16 
(1.8%) on TDF (P = 0.051); all fractures were due to trauma 
and unrelated to study drug. No discontinuations due to BMD 
decreases occurred with TAF. Between weeks 48 and 144, 6 
men discontinued TDF because of a .5% decrease in BMD 
(ages ranged from 20 to 50 years). At all time points, median 
percent changes from baseline in serum parathyroid hormone 
(PTH) were lower with TAF than TDF (week 144: TAF
FIGURE 2. Key safety endpoints. A, Measures of bone safety: BMD and PTH; (B) Measures of renal safety: eGFR and proteinuria;
(C) measures of renal safety: tubular proteinuria. P , 0.001 for all parameters at all time points. IQR, interquartile range.
applied to all participants. Tubulopathy was not identified in
any participant on TAF. Seven cases identified in the TDF
group included 4 of the 12 participants who discontinued
treatment because of renal-related AEs. Notably, 1 TDF-
taking participant reported to have acquired Fanconi syn-
drome did not meet the validation criteria. Taken together,
these longer-term safety data support the hypothesis that
circulating levels of TFV are responsible for bone and renal
toxicity with TDF, and markedly reduced TFV levels
delivered by TAF minimize such exposure.
Treatment with TDF has consistently been associated
with lower lipids compared with other regimens in treatment-
naive or virologically suppressed individuals.21,22 This TDF
lipid effect is believed to be associated with plasma levels of
TFV.21,23,24 In this study, participants receiving TAF had
greater increases in TC, HDL, low-density lipoprotein, and
triglycerides, likely related to significant reductions in plasma
TFV concentrations. Changes in fasting lipid levels are most
accurately reported not as an adverse effect of TAF but rather
as an effect of an absence of high plasma TFV concentrations.
Importantly in this study, no treatment differences were
observed in the TC:HDL ratios between groups, which is
included in cardiovascular risk predictors in the general
population such as the Framingham risk and American
College of Cardiology/American Heart Association (ACC/
AHA) risk calculators25 and associated with the risk for
cardiovascular disease in HIV-infected individuals.26 We
have previously reported that there is no difference between
the TAF vs TDF groups in atherosclerotic cardiovascular
disease estimated cardiovascular risk, eligibility for statins, or
the incidence of cardiovascular AEs.27
Overall, in these large, international, randomized trials
following 3 years of treatment, 84% of those assigned to TAF
remained virologically suppressed. TAF was superior to TDF
in virologic efficacy and produced significantly more favor-
able changes in multiple markers of renal and bone health.
Despite the increases in lipids in the TAF group, there were
no differences between groups in TC:HDL ratio, a predictor
FIGURE 3. Fasting lipid parameters. A, Baseline lipid levels are shown in the lighter color. Increases from baseline are shown in the
darker color at each time point. B, Median TC:HDL ratio is shown at each time point.
because of AEs, these AEs leading to discontinuation 
happened early in the TAF group, whereas those on TDF 
continued to experience AEs leading to discontinuation 
steadily through week 144.
Moreover, TAF continued to demonstrate significantly 
less impact on measures of bone and renal safety than TDF. 
Through 144 weeks of treatment with TAF, clinical bone and 
renal AEs in the TAF group were rare. No participants on 
TAF discontinued study drug because of bone loss, compared 
with 6 participants on TDF. Significant differences between 
TAF and TDF in mean changes from baseline in total hip and 
lumbar spine BMD observed at week 48 persisted through 
week 144. Significant differences between groups in median 
percent changes from baseline in PTH were noted early and 
through 144 weeks, and the median levels of PTH continued 
to increase for both groups. However, the median PTH levels 
stayed within the normal range. The relationship between the 
observed changes in BMD and PTH is unknown.
Markers of renal function also continued to be more 
favorable with TAF compared with TDF. A small and rapid 
decline in CrCl is expected with administration of cobicistat, 
which is known to interfere with tubular secretion of 
creatinine, thereby leading to an increase in serum creatinine 
and decrease in eGFR without an effect on actual GFR.19 In 
this study, an expected decline in CrCl was observed in both 
groups but was more pronounced with TDF, as demonstrated 
by a significant difference favoring TAF in percentage of 
participants who had a CrCl decline of $25%,20 a change 
most likely due to the impact of cobicistat on renal trans-
porters of creatinine.19 No participants in the TAF group 
discontinued because of renal AEs compared with 12 in the 
TDF group, a statistically significant difference reflecting the 
lack of TFV-associated nephrotoxicity with TAF.
Proximal renal tubular dysfunction, or tubulopathy, is 
a rare toxicity associated with TDF and was reported by 
investigators in 4 participants receiving this agent. With no 
standardized diagnostic criteria for tubulopathy, an assess-
ment of measures of proximal renal tubular dysfunction was
of cardiovascular risk. These longer-term data support the use 
of E/C/F/TAF as a safe, well-tolerated, and durable regimen 
for initial and ongoing HIV-1 treatment.
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